The launch of Bristol-Myers Squibb’s (BMS) Yervoy (ipilimumab) in 2011 marked the first new branded treatment for metastatic melanoma in 13 years and the first immuno-oncology product approved for any indication.
Yervoy is a monoclonal antibody (mAb) directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and its activity boosts the immune system's ability to fight tumours. The drug is heralded as a scientific breakthrough and it helped extend survival in patients with advanced melanoma.
Go deeper with GlobalData
Yervoy’s four-dose treatment costs roughly $140,000. Yervoy ran into a series of reimbursement blocks in markets such as the UK and Australia that resulted in delayed approvals, with discounts being offered by the company to appease cost-effectiveness watchdogs such as the UK’s National Institute for Health and Care Excellence (NICE). In subsequent years, programmed death-1 (PD-1) drugs Opdivo (nivolumab) and Keytruda (pembrolizumab) were approved in melanoma, which were both deemed to be safer and more efficacious than Yervoy. The advent of PD-1-based regimens, together with the notoriety of Yervoy for having substantial toxicity levels, resulted in the drug being progressively side-lined.
BMS is pursuing a next-generation anti-CTLA-4 agent devoid of the unfavourable toxicity profile of Yervoy. New patents were filed by BMS in 2014 regarding the design or modification of anti-CTLA-4 antibodies, to enhance their activity and reduce toxicity. This move alludes to the company’s interest in securing a position for anti-CTLA-4 antibodies within the future treatment paradigm.
A Phase I/IIa trial has recently been registered by BMS for BMS-986218, which involves 452 patients. This is a high number for a first-in-human study. According to the National Cancer Institute, BMS-986218 is an engineered version of Yervoy. Notably, the study design compares Yervoy and BMS-986218 monotherapy, as well as BMS-986218 combined with Opdivo.
See Also:
Success of BMS’ Phase I/IIa trial has the potential to invigorate BMS’ position as a leader in anti-CTLA-4 drugs and to fend off competitor AstraZeneca’s tremelimumab, which is an anti-CTLA-4 mAb. BMS-986218 has an edge over tremelimumab with respect to clinical development in melanoma, as BMS has established its presence in that setting. Notably, tremelimumab is a drug that has previously been shown to be ineffective as first-line treatment in patients with advanced melanoma. It is is currently in Phase III development for other cancer indications besides.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBMS’ strategy to develop a second anti-CTLA-4 mAb offers an avenue to improve upon the currently available PD-1/CTLA-4 combinatorial treatments, such as BMS’ Opdivo + Yervoy. The race for developing the next-generation anti-CTLA-4 drug is heating up, and the readout from the BMS trial is thereby eagerly awaited.
Related Company Profiles
Bristol-Myers Squibb Co
BMS AS
Nice S.p.A.
AstraZeneca Plc